Ankylosing Spondylitis Treatment Market

Ankylosing Spondylitis Treatment Market Outlook and Key Findings

• The global ankylosing spondylitis treatment market is expected to grow at a steady CAGR through 2030
• Ankylosing spondylitis treatment market players focusing on innovation & regulatory approvals
• North America and Europe collectively account for more than 50% of market share – revenue concentrated in the US and EU4
• Inclusion of nanocurcumin to bolster the ankylosing spondylitis treatment market in the forecast period

Ankylosing Spondylitis Treatment Market Analysis

As per Arthritis Care & Research,almost 20-50% of people suffering from ankylosing spondylitis are reported to show spinal progression of certain level in the last two years of follow-up.

The TNF inhibitor treatments and NSAIDs (Non-steroid anti-inflammatory drugs) have been cornerstone therapies regarding managing ankylosing spondylitis and other types of inflammatory arthritis conditions.

The European Congress of Rheumatology (EULAR) annual meeting presented a French study raising a concern that rheumatologists, in spite of being knowledgeable about biosimilars, abstain from switching over to them due to lack of confidence in this treatment option.

On the other hand, European Journal of Integrative Medicine, Sep 2019, stated that Moxibustion, a type of heat therapy combined with traditional treatments is likely to provide short-term benefit to the ones affected by ankylosing spondylitis. This therapy is already put into practice all over East Asia.

Besides, findings at the Universita Degli Studi del Molise (Italy) state that physiotherapy is advantageous for ankylosing spondylitis-affected patients.

Though anti-inteleukin medications and anti-tumor necrosis have improved prognosis for a sizable number of patients; physiotherapy helps those who do not respond positively to these drugs. Moreover, modern day treatments press for physical rehabilitation and therapy.

Of late, research conducted at the University of Medical Sciences (Iran) concluded that T reg cells (suppressing the immune system) were upregulated in ankylosing spondylitis-affected patients who received a dose of nanocurcumin for 4 months in a row. Turmeric contains curcumin in the form of a naturally-occurring yellow colored substance.

The factors mentioned above are expected to compel the governments to divert a greater portion of their revenue towards extensive research, thereby driving the ankylosing spondylitis treatment market.

Market Players are Focusing on R&D and Innovations

The ankylosing spondylitis treatment market players are focusing on innovation and approval to gain a competitive edge over one another.

This trend is bound to help the ankylosing spondylitis market stand in a better stead between 2020 and 2030.

For instance –

• In Jun 2020, Germany-based real-world data stated that Simponi (golimumab), a TNF inhibitor, is one of the most effective therapies for ankylosing spondylitis-affected patients.
• In Feb 2020, Taltz (ixekizumab) was approved by Health Canada for treating adults with ankylosing spondylitis who weren’t responsive to traditional therapies.
• In Dec 2019, Avsola (infliximab-axxq), biosimilar to Remicade (infliximab) for treating ankylosing spondylitis, was approved by the US FDA. Amgen is the maker of this biosimilar.
• In Nov 2019, AbbVie, at 2019 American College of Rheumatology (ACR)/Association for Rheumatology Professionals (ARP) Annual Meeting, presented positive results from phase 2 & 3 SELECT-AXIS 1 trial for treatment against ankylosing Spondylitis in the form of Rinvoq.
• In Nov 2019, the US FDA approved Abrilada (adalimumab-afzb), biosimilar to Humira (adalimumab) for treating people infected with 7 inflammatory diseases (ankylosing spondylitis included). Abrilada is credited to Pfizer.
• In Sep 2019, outcome of phase 2 study that examined filgotinib suggested that oral therapy could prove to be an effective treatment regarding active ankylosing spondylitis.

Ankylosing Spondylitis Treatment Market Trends

The healthcare industry is moving towards extensive research with regards to ankylosing spondylitis, so as to continue with the geometric progression on the count of innovations.

For instance –

• In Jul 2020, scientists at Rockefeller University inferred that newly discovered “PRIME cells” are capable of tamping down the inflammation caused due to rheumatoid arthritis. As such, one could foretell and treat rheumatoid arthritis flares. This discovery is bound to open doors to invention of biosimilars to treat this kind of spondylitis before it reaches the advanced stage.
• In Jun 2020, Celltrion Healthcare received recommendation from CHMP (Committee for Medicinal Products for Human Use) for use of Remsima in ankylosing spondylitis.
• In Oct 2019, SAA (Spondylitis Association of America) entered into partnership with PatientPoint for improving education regarding spondylitis and also extend support to rheumatology practices all over the US.

Ankylosing Spondylitis Treatment Market: Regional Analysis

• North America holds the largest share of ankylosing spondylitis treatment market due to feasible reimbursement scenario in the US coupled with massive approvals for biosimilars by the US FDA.
• European ankylosing spondylitis treatment market is benefitting from governments investing in research regarding effective treatment for ankylosing spondylitis.
• Asia Pacific is expected to witness a linear transition in the ankylosing spondylitis treatment market due to countries like India and China moving from indolence to awareness regarding ankylosing spondylitis treatment

Major Players in the Ankylosing Spondylitis Treatment Market

The ankylosing spondylitis treatment market players have been devising biosimilars to combat ankylosing spondylitis.

Also, branded drugs’ patent expiry is opening doors for biosimilars. For instance – Remicade expired in 2015. This resulted in Inflectra getting introduced in 2016. The year 2017 witnessed introduction of Renflexis. Likewise, in 2019, Avsola got introduced.

The major players in the ankylosing spondylitis treatment market include:

• Wyeth
• Mitsubishi Tanabe
• Schering-Plough
• Takeda
• Amgen
• Centocor
• Abbott
• Eisai
• Pfizer

Ankylosing Spondylitis Treatment Market: The Way Forward

The ankylosing spondylitis treatment market, as stated by FMI, is expected to witness a steady growth rate between 2020 and 2030.

The market players are working on war footing to devise medications for ankylosing spondylitis.

Inorganic growth parameters could also be pondered about. For instance – strategic partnerships across various geographies could help in reaching out to more number of patients

Table of Content

• 1. Executive Summary
• 2. Market Overview
• 3. Key Market Trends
• 4. Key Success Factors
• 5. Global Market - Pricing Analysis
• 6. Global Market Demand (in Value or Value in USD Million) Analysis 2015 to 2019 and Forecast 2020 to 2030
• 7. Market Background
• 8. Global Market Analysis 2015 to 2019 and Forecast 2020 to 2030, by Drug Class
  • 8.1. Disease-Modifying Antirheumatic Drugs (DMARDs)
  • 8.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 8.3. Biologics
• 9. Global Market Analysis 2015 to 2019 and Forecast 2020 to 2030, by Route of Administration
  • 9.1. Oral
  • 9.2. Parenteral
• 10. Global Market Analysis 2015 to 2019 and Forecast 2020 to 2030, by Application
  • 10.1. Juveniles
  • 10.2. Adults
• 11. Global Market Analysis 2015 to 2019 and Forecast 2020 to 2030, by Region
  • 11.1. North America
  • 11.2. Latin America
  • 11.3. Europe
  • 11.4. Middle East and Africa (MEA)
  • 11.5. East Asia
  • 11.6. South Asia
  • 11.7. Oceania
• 12. North America Market Analysis 2015 to 2019 and Forecast 2020 to 2030
• 13. Latin America Market Analysis 2015 to 2019 and Forecast 2020 to 2030
• 14. Europe Market Analysis 2015 to 2019 and Forecast 2020 to 2030
• 15. South Asia Market Analysis 2015 to 2019 and Forecast 2020 to 2030
• 16. East Asia Market Analysis 2015 to 2019 and Forecast 2020 to 2030
• 17. Oceania Market Analysis 2015 to 2019 and Forecast 2020 to 2030
• 18. Middle East and Africa Market Analysis 2015 to 2019 and Forecast 2020 to 2030
• 19. Key and Emerging Countries Market Analysis 2015 to 2019 and Forecast 2020 to 2030
• 20. Market Structure Analysis
• 21. Competition Analysis
  • 21.1. AbbVie, Inc.
  • 21.2. Amgen, Inc.
  • 21.3. Pfizer, Inc.
  • 21.4. Novartis AG
  • 21.5. Eli Lilly and Company
  • 21.6. UCB, Inc.
  • 21.7. Johnson & Johnson Services, Inc.
  • 21.8. Merck & Co., Inc.
  • 21.9. Janssen Pharmaceuticals Inc
  • 21.10. Sandoz International GmbH
• 22. Assumptions and Acronyms Used
• 23. Research Methodology

List of Tables

Table 01: Global Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, by Drug Class

Table 02: Global Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Route of Administration

Table 03: Global Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, by Application

Table 04: Global Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Region

Table 05: North America Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 06: North America Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

Table 7: North America Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 8: North America Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Application

Table 9: Latin America Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 10: Latin America Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

Table 11: Latin America Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 12: Latin America Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Application

Table 13: Europe Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 14: Europe Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

Table 15: Europe Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 16: Europe Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Application

Table 17: East Asia Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 18: East Asia Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

Table 19: East Asia Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 20: East Asia Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Application

Table 21: South Asia Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 22: South Asia Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

Table 23: South Asia Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 24: South Asia Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Application

Table 25: Oceania Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 26: Oceania Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

Table 27: Oceania Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 28: Oceania Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Application

Table 29: MEA Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 30: MEA Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

Table 31: MEA Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration

Table 32: MEA Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Application

List of Figures

Figure 01: Global Market Value (US$ Mn) Analysis, 2015–2019

Figure 02: Global Market Value (US$ Mn) & Y-o-Y Growth (%) Analysis, 2020–2030

Figure 03: Global Market Absolute $ Opportunity Analysis, 2020–2030

Figure 04: Global Market Value Analysis by Drug Class –2020 & 2030

Figure 05: Global Market Y-o-Y Growth Projections by Drug Class , 2020 – 2030

Figure 06: Global Market Attractiveness Analysis By Drug Class, 2020-2030,

Figure 07: Global Market Analysis by Route of Administration –2020 & 2030

Figure 08: Global Market Y-o-Y Growth Projections by Route of Administration , 2020 – 2030

Figure 09: Global Market Attractiveness Analysis 2020-2030, by Route of Administration

Figure 10: Global Market Analysis by Application –2020 & 2030

Figure 11: Global Market Y-o-Y Growth Projections by Application , 2020 – 2030

Figure 12: Global Market Attractiveness Analysis 2020-2030, By Application

Figure 13: Global Market Analysis by Region–2020 & 2030

Figure 14: Global Market Y-o-Y Growth Projections by Region, 2020 – 2030

Figure 15: Global Market Attractiveness Analysis 2020-2030, By Region

Figure 16: North America Market Value (US$ Mn) Analysis, 2015-2019

Figure 17: North America Market Value (US$ Mn) & Y-o-Y Growth (%), 2020–2030

Figure 18: North America Market Attractiveness Analysis 2020-2030, by Country

Figure 19: North America Market Attractiveness Analysis 2020-2030, by Drug Class

Figure 20: North America Market Attractiveness Analysis 2020-2030, Route of Administration

Figure 21: North America Market Attractiveness Analysis 2020-2030, by Application

Figure 22: Latin America Market Value (US$ Mn) Analysis, 2015-2019

Figure 23: Latin America Market Value (US$ Mn) & Y-o-Y Growth (%), 2020–2030

Figure 24: Latin America Market Attractiveness Analysis 2020-2030, by Country

Figure 25: Latin America Market Attractiveness Analysis 2020-2030, by Drug Class

Figure 26: Latin America Market Attractiveness Analysis 2020-2030, Route of Administration

Figure 27: Latin America Market Attractiveness Analysis 2020-2030, by Application

Figure 28: Europe Market Value (US$ Mn) Analysis, 2015-2019

Figure 29: Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2020–2030

Figure 30: Europe Market Attractiveness Analysis 2020-2030, by Country

Figure 31: Europe Market Attractiveness Analysis 2020-2030, by Drug Class

Figure 32: Europe Market Attractiveness Analysis 2020-2030, Route of Administration

Figure 33: Europe Market Attractiveness Analysis 2020-2030, by Application

Figure 34: East Asia Market Value (US$ Mn) Analysis, 2015-2019

Figure 35: East Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2020–2030

Figure 36: East Asia Market Attractiveness Analysis 2020-2030, by Country

Figure 37: East Asia Market Attractiveness Analysis 2020-2030, by Drug Class

Figure 38: East Asia Market Attractiveness Analysis 2020-2030, Route of Administration

Figure 39: East Asia Market Attractiveness Analysis 2020-2030, by Application

Figure 40: South Asia Market Value (US$ Mn) Analysis, 2015-2019

Figure 41: South Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2020–2030

Figure 42: South Asia Market Attractiveness Analysis 2020-2030, by Country

Figure 43: South Asia Market Attractiveness Analysis 2020-2030, by Drug Class

Figure 44: South Asia Market Attractiveness Analysis 2020-2030, Route of Administration

Figure 45: South Asia Market Attractiveness Analysis 2020-2030, by Application

Figure 46: Oceania Market Value (US$ Mn) Analysis, 2015-2019

Figure 47: Oceania Market Value (US$ Mn) & Y-o-Y Growth (%), 2020–2030

Figure 48: Oceania Market Attractiveness Analysis 2020-2030, by Country

Figure 49: Oceania Market Attractiveness Analysis 2020-2030, by Drug Class

Figure 50: Oceania Market Attractiveness Analysis 2020-2030, Route of Administration

Figure 51: Oceania Market Attractiveness Analysis 2020-2030, by Application

Figure 52: MEA Market Value (US$ Mn) Analysis, 2015-2019

Figure 53: MEA Market Value (US$ Mn) & Y-o-Y Growth (%), 2020–2030

Figure 54: MEA Market Attractiveness Analysis 2020-2030, by Country

Figure 55: MEA Market Attractiveness Analysis 2020-2030, by Drug Class

Figure 56: MEA Market Attractiveness Analysis 2020-2030, Route of Administration

Figure 57: MEA Market Attractiveness Analysis 2020-2030, by Application

Figure 58: U.S. Market Value Proportion Analysis

Figure 59: Global Vs. U.S. Growth Comparison

Figure 60: U.S. Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 61: U.S. Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 62: U.S. Market Share Analysis (%) By Application, 2020 & 2030

Figure 63: Canada Market Value Proportion Analysis

Figure 64: Canada Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 65: Canada Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 66: Canada Market Share Analysis (%) By Application, 2020 & 2030

Figure 67: Global Vs. Canada Growth Comparison

Figure 68: Brazil Market Value Proportion Analysis

Figure 69: Brazil Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 70: Brazil Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 71: Brazil Market Share Analysis (%) By Application, 2020 & 2030

Figure 72: Global Vs. Brazil Growth Comparison

Figure 73: Mexico Market Value Proportion Analysis

Figure 74: Mexico Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 75: Mexico Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 76: Mexico Market Share Analysis (%) By Application, 2020 & 2030

Figure 77: Global Vs. Mexico Growth Comparison

Figure 78: Argentina Market Value Proportion Analysis

Figure 79: Argentina Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 80: Argentina Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 81: Argentina Market Share Analysis (%) By Application, 2020 & 2030

Figure 82: Global Vs. Argentina Growth Comparison

Figure 83: U.K. Market Value Proportion Analysis

Figure 84: U.K. Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 85: U.K. Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 86: U.K. Market Share Analysis (%) By Application, 2020 & 2030

Figure 87: Global Vs. U.K. Growth Comparison

Figure 88: Germany Market Value Proportion Analysis

Figure 89: Germany Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 90: Germany Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 91: Germany Market Share Analysis (%) By Application, 2020 & 2030

Figure 92: Global Vs. Germany Growth Comparison

Figure 93: France Market Value Proportion Analysis

Figure 94: France Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 95: France Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 96: France Market Share Analysis (%) By Application, 2020 & 2030

Figure 97: Global Vs. France Growth Comparison

Figure 98: Italy Market Value Proportion Analysis

Figure 99: Italy Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 100: Italy Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 101: Italy Market Share Analysis (%) By Application, 2020 & 2030

Figure 102: Global Vs. Italy Growth Comparison

Figure 103: Spain Market Value Proportion Analysis

Figure 104: Spain Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 105: Spain Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 106: Spain Market Share Analysis (%) By Application, 2020 & 2030

Figure 107: Global Vs. Spain Growth Comparison

Figure 108: Russia Market Value Proportion Analysis

Figure 109: Russia Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 110: Russia Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 111: Russia Market Share Analysis (%) By Application, 2020 & 2030

Figure 112: Global Vs. Russia Growth Comparison

Figure 113: China Market Value Proportion Analysis

Figure 114: China Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 115: China Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 116: China Market Share Analysis (%) By Application, 2020 & 2030

Figure 117: Global Vs. China Growth Comparison

Figure 118: Japan Market Value Proportion Analysis

Figure 119: Japan Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 120: Japan Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 121: Japan Market Share Analysis (%) By Application, 2020 & 2030

Figure 122: Global Vs. Japan Growth Comparison

Figure 123: South Korea Market Value Proportion Analysis

Figure 124: South Korea Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 125: South Korea Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 126: South Korea Market Share Analysis (%) By Application, 2020 & 2030

Figure 127: Global Vs. South Korea Growth Comparison

Figure 128: India Market Value Proportion Analysis

Figure 129: India Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 130: India Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 131: India Market Share Analysis (%) By Application, 2020 & 2030

Figure 132: Global Vs. India Growth Comparison

Figure 133: Indonesia Market Value Proportion Analysis

Figure 134: Indonesia Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 135: Indonesia Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 136: Indonesia Market Share Analysis (%) By Application, 2020 & 2030

Figure 137: Global Vs. Indonesia Growth Comparison

Figure 138: Thailand Market Value Proportion Analysis

Figure 139: Thailand Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 140: Thailand Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 141: Thailand Market Share Analysis (%) By Application, 2020 & 2030

Figure 142: Global Vs. Thailand Growth Comparison

Figure 143: Malaysia Market Value Proportion Analysis

Figure 144: Malaysia Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 145: Malaysia Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 146: Malaysia Market Share Analysis (%) By Application, 2020 & 2030

Figure 147: Global Vs. Malaysia Growth Comparison

Figure 148: Australia Market Value Proportion Analysis

Figure 149: Australia Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 150: Australia Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 151: Australia Market Share Analysis (%) By Application, 2020 & 2030

Figure 152: Global Vs. Australia Growth Comparison

Figure 153: New Zealand Market Value Proportion Analysis

Figure 154: New Zealand Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 155: New Zealand Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 156: New Zealand Market Share Analysis (%) By Application, 2020 & 2030

Figure 157: Global Vs. New Zealand Growth Comparison

Figure 158: South Africa Market Value Proportion Analysis

Figure 159: South Africa Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 160: South Africa Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 161: South Africa Market Share Analysis (%) By Application, 2020 & 2030

Figure 162: Global Vs. South Africa Growth Comparison

Figure 163: Turkey Market Value Proportion Analysis

Figure 164: Turkey Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 165: Turkey Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 166: Turkey Market Share Analysis (%) By Application, 2020 & 2030

Figure 167: Global Vs. Turkey Growth Comparison

Figure 168: GCC Market Value Proportion Analysis

Figure 169: GCC Market Share Analysis (%) By Drug Class, 2020 & 2030

Figure 170: GCC Market Share Analysis (%) By Route of Administration, 2020 & 2030

Figure 171: GCC Market Share Analysis (%) By Application, 2020 & 2030

Figure 172: Global Vs. GCC Growth Comparison